China Biologic Products (CBPO) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2015
February 25, 2016 5:00 PM ESTBEIJING, Feb. 25, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2015.
Fourth Quarter 2015 Financial Highlights
Total sales in the fourth quarter of 2015 increased by 22.6% in RMB terms, or 17.8% in USD terms, to $68.3 million from $58.0 million in the same quarter of 2014. Gross profit increased by 11.6% to $41.3 million from $37.0 million in the same quarter of 2014. Gross margin decreased to 60.5% in the fourth... More


